Suzhou Thery Pharmaceutical Co., Ltd.

To compare the pharmacokinetic characteristics and safety of the investigational drug semaglutide injection (specification: 1.5mL:1mg) and the control drug semaglutide injection (trade name: Wegovy®, specification: 1.5mL:1mg) in healthy Chinese adult subjects after a single subcutaneous injection.

This study used BUFFERIN Combination Tab. A81 developed by Suzhou Terui Pharmaceutical Co., Ltd. as the test preparation and BUFFERIN Combination Tab. A81 developed by Lion Corporation as the reference preparation to evaluate whether the test preparation and the reference preparation are bioequivalent under fasting and postprandial administration conditions. The safety of the test preparation and the reference preparation in healthy subjects was observed.

A single-center, randomized, open, two-period crossover, single-dose design was used to compare the differences in absorption extent and rate between dapoxetine hydrochloride tablets (specification: 30 mg) produced by Suzhou Terui Pharmaceutical Co., Ltd. and dapoxetine hydrochloride tablets (trade name: Priligy®, specification: 30 mg) certified by Berlin-Chemie AG in healthy Chinese people under fasting and fed conditions, to evaluate the bioequivalence of the two oral preparations under fasting and fed conditions, and to evaluate the safety of dapoxetine hydrochloride tablets (specification: 30 mg) produced by Suzhou Terui Pharmaceutical Co., Ltd.